NEW ORLEANS — There are multiple ongoing clinical trials that could potentially influence the way cardiologists treat patients with atrial fibrillation and ACS, Roxana Mehran, MD, associate medical editor of Cardiology Today's Intervention, said at the American Heart Association Scientific Sessions.
In this video, Mehran, director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine, discusses the results of PIONEER AF-PCI, which evaluated patients with atrial fibrillation undergoing PCI who received rivaroxaban-based strategies (Xarelto, Janssen) and demonstrated reduced bleeding vs. warfarin.
In addition, Mehran mentions the AUGUSTUS and RE-DUAL trials and what she envisions the future of AF and ACS treatment to look like.
“This is the beginning of a new era of combining novel anticoagulant therapies [and] withdrawing aspirin in some of these patients who have high risk of bleeding and really rethinking that triple therapy arm,” she told Cardiology Today. “These [trials] are going to give us so much more information.”
Gibson CM, et al. LBCT.02 – Pioneering the Future of HeART Interventions. Presented at: American Heart Association Scientific Sessions; Nov. 12-16, 2016; New Orleans.
Disclosures: Mehran reports receiving research grants from AstraZeneca, Bayer, Bristol-Myers Squibb, CSL Behring and Eli Lilly. Mehran also reports serving as a consultant and on advisory boards for Abbott Laboratories, Janssen, Osprey Medical and Watermark Research Partners.